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In sarcoidosis, increased Th17 cell fractions have been reported in bronchoalveolar lavage fluid, and elevated numbers of Th17
cells producing IFN-𝛾 have been observed in peripheral blood. The balance between Th1, Th17, and FoxP3+ CD4+ T cell subsets
in sarcoidosis remains unclear. Bronchoalveolar lavage fluid cells, from 30 patients with sarcoidosis, 18 patients with other diffuse
parenchymal lung diseases, and 15 healthy controls, were investigated with flow cytometry for intracellular expression of FoxP3. In a
subset of the patients, expression of the cytokines IL17A and IFN-𝛾was investigated.The fractions of FoxP3+ CD4+ T cells andTh17
cells were both lower in sarcoidosis compared to controls (𝑃 = 0.017 and 𝑃 = 0.011, resp.).The proportion ofTh17 cells positive for
IFN-𝛾was greater in sarcoidosis than controls (median 72.4% versus 31%, 𝑃 = 0.0005) and increased with radiologic stage (𝑁 = 23,
rho = 0.45, and 𝑃 = 0.03). IFN-𝛾+Th17 cells were highly correlated with Th1 cells (𝑁 = 23, rho = 0.64, and 𝑃 = 0.001), and the
ratio of IFN-𝛾+Th17/FoxP3+ CD4+ T cells was prominently increased in sarcoidosis. IFN-𝛾+Th17 cells may represent a pathogenic
subset of Th17 cells, yet their expression of IFN-𝛾 could be a consequence of a Th1-polarized cytokine milieu. Our results indicate
a possible immune cell imbalance in sarcoidosis.
1. Introduction
Sarcoidosis is a granulomatous disease with a predilection
for the lungs and lymphatic tissue and is characterized by
increased fractions and number of IFN-𝛾-producing T helper
cells (Th1 cells) in inflamed tissue [1, 2]. A current hypothesis
about the etiology is that an inhaled antigen, which may
be persistent and poorly degradable, provokes a Th1 type
immune reaction. Both mycobacterial proteins and DNA
fromPropionibacteriumacneshave been identified as possible
candidate antigens [3].
The discovery of the CD4+ T cell subsets regulatory T
cells and laterTh17 cells has modified the traditional concept
of Th1- or Th2-polarized adaptive immune responses [4–
7]. Whereas regulatory T cells, which are characterized by
expression of the transcription factor FoxP3, have a pivotal
role in maintaining immune homeostasis and preventing
autoimmunity [8, 9];Th17 cells produce the potent proinflam-
matory cytokine IL-17 and have a crucial role in host immu-
nity towards extracellular bacterial and fungal pathogens [10].
Both Th17 cells and FoxP3+ CD4+ T cells have been impli-
cated in various human diseases with suspected autoimmune
etiology, such as rheumatoid arthritis, inflammatory bowel
disease, multiple sclerosis, and psoriasis [10–12]. Intriguingly,
the putative sarcoidosis antigensMycobacterium tuberculosis
and Propionibacterium acnes have both been reported to
trigger strong Th17 responses [10]. Furthermore, Th17 cells
recruit Th1 cells to the lungs during a mycobacterial infec-
tion and are required for proper formation of granulomas
[13].
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Increased Th17 cell fractions in peripheral blood and
bronchoalveolar lavage fluid (BALF), and surrounding the
central core of the granuloma on tissue specimens have been
reported in sarcoidosis [14]. Within theTh17 cell population,
there are subsets secreting different cytokines, including
TNF-𝛼 and IFN-𝛾, with distinct effector functions [15]. IFN-
𝛾
+ Th17 cells have been observed in elevated numbers in
inflamed tissue in various conditions in man and mice [16–
18]. In sarcoidosis, peripheral bloodTh17 cells were reported
to contain an increased fraction of IFN-𝛾+ cells compared to
controls, although the IFN-𝛾median fluorescent intensity of
these cells was decreased [19].
Reports on regulatory T cells in sarcoidosis are conflict-
ing. FoxP3+ CD4+ T cells are present in increased numbers
in and around granulomas [20]. However, in BALF both
increased [21] and decreased frequencies [22] have been
reported. Interestingly, an imbalance of the regulatory T
cells and the proinflammatory Th17 cells may contribute to
the pathophysiology of autoimmune diseases [23–26]. These
two CD4+ T cell subsets share common promoting factors
and chemokine receptors that constitute developmental and
functional links [27, 28].
In this study, we investigated the proportion of CD4+ T
cell subsets expressing FoxP3 and, upon stimulation, IL17 or
IFN-𝛾 in patients with sarcoidosis, other DPLDs, and healthy
control subjects. The aim of the study was to investigate the
fractions of FoxP3+ CD4+ T cells,Th1,Th17, and IFN-𝛾+Th17
cells in BALF and to assess the hypothesis about an imbalance
between these subsets in sarcoidosis. We also investigated if
these phenotypes correlated with the radiological staging of
the sarcoidosis.
2. Materials and Methods
2.1. Study Population. Patients who underwent diagnostic
workup with bronchoscopy and bronchoalveolar lavage in
our clinic between November 2010 and September 2012
for possible diffuse parenchymal lung disease (DPLD) were
eligible for inclusion in the study if they had a BALF
lymphocyte fraction greater than 5% of the leucocytes and
were not receiving systemic therapy with corticosteroid or
methotrexate. We included 30 patients with sarcoidosis and
18 patients with other DPLDs (hypersensitivity pneumonitis:
𝑁 = 5; idiopathic pulmonary fibrosis: 𝑁 = 2; non-
specific interstitial pneumonia: 𝑁 = 1; connective tissue
disease or medication-associated lung disease: 𝑁 = 2;
pneumoconiosis: 𝑁 = 1; unspecified DPLD: 𝑁 = 7).
Patients with a concluding non-DPLD clinical diagnosis were
not included. For this study, the diagnosis of sarcoidosis
was considered certain if clinical presentation and thoracic
imaging were consistent with pulmonary sarcoidosis and
there were noncaseating granulomas in endobronchial or
transbronchial biopsy specimens or from endobronchial
ultrasound transbronchial aspirations of enlarged hilar or
mediastinal lymph nodes [29]. Histological demonstration
of granuloma was not required for patients with classic
features of Lo¨fgren’s syndrome, defined as bilateral hilar lym-
phadenopathy with fever, erythema nodosum, and/or ankle
arthritis.There were 3, 14, 9, 2, and 2 sarcoidosis patients with
radiological staging 0, 1, 2, 3, and 4, respectively, according
to Scadding [30], and 5 patients presented with Lo¨fgren’s
syndrome.
Investigation of intracellular expression of IL-17A and
IFN-𝛾 after mitogen stimulation was performed in a sub-
group of the patients: sarcoidosis: 𝑁 = 23 (3 patients with
Lo¨fgren’s syndrome); other DPLDs:𝑁 = 11 (hypersensitivity
pneumonitis: 𝑁 = 3; idiopathic pulmonary fibrosis: 𝑁 =
1; connective tissue disease or medication associated lung
disease:𝑁 = 2; unspecified DPLD:𝑁 = 5).
Eight male and 7 female healthy control subjects were
recruited by advertising on the hospital website. All were
nonsmokers with no history of allergy, asthma, or other lung
diseases, and had normal chest radiography. All healthy con-
trol subjects and all patients except two were Caucasians of
Scandinavian descent. Characteristics of the study population
are displayed in Table 1.
Written informed consent was obtained from all subjects,
and the study was approved by the Regional Ethics Commit-
tee (Ref.nr.: 2010/1939-4).
2.2. BAL Procedure. BAL was performed as previously
described [31]. The choice of the lavage site was guided by
the location of parenchymal pathology on high resolution
computed tomography (HRCT), or if indifferent, the right
middle lobe was chosen. With the bronchoscope in a wedged
position in a segmental bronchus, 2-3 aliquots of 60mL
phosphate-buffered saline (hospital pharmacy at Haukeland
University Hospital, Bergen, Norway) were instilled and
retrieved by applying gentle suction. The second and third
fractions of BALF were pooled and filtered through a Falcon
Cell strainerwith 100𝜇mnylonmesh (Becton,Dickinson and
Company (BD) Biosciences, Mountain view, CA) and stored
at 4∘C until processing within 4 hours of collection.
2.3. Total and Differential Cell Counts. ADVIA 120 Hema-
tology System (Siemens AG, Erlangen, Germany) was used
for determination of total cell count. Smears were prepared
by cytocentrifugation (Hettich Universal 320, DJB Labcare
Ltd., Buckinghamshire, England) and stained with May
Gru¨nwald/Giemsa. Differential cell counts were done on a
minimum of 300 cells.
2.4. Mitogen Stimulation. The cells were processed accord-
ing to the recommendations in the human Th17/Treg
phenotyping kit (BD Biosciences) (see supplementary
Table 1 in Supplementary Material available online at
http://dx.doi.org/10.1155/2014/438070; tube 4). Briefly, 1-2
×10
6 cells were incubated at 37∘C and 5% CO
2
for 5 hours
in Roswell Park Memorial Institute medium (RPMI) with
10% fetal calf serum (FCS) with and without phorbol-12-
myristate-13-acetate (PMA) at 50 ng/mL and ionomycin
1 𝜇g/mL, in the presence of GolgiStop, a protein transport
inhibitor (BD Biosciences). The cells were fixed by BD FoxP3
buffer set, buffer A (BD Biosciences), and stored for <6
months in a medium of 90% FCS and 10% dimethyl sulfoxide
(DMSO) at −80∘C until batch processing.
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Table 1: Basic characteristics of the study population.
Characteristic Sarcoidosis(𝑁 = 30)
Other DPLDs
(𝑁 = 18)
Healthy controls
(𝑁 = 15) 𝑃
∗
Age, years (range) 46 (37–56)## 63 (48–72)§§ 35 (30–49) 0.03
Sex (male/female) 23/7 11/7 8/7 0.25
Smokers (current/former/never) 1/9/20 4/7/7 0/3/12 0.03∗∗
FEV1, percentage of predicted 80 (68–90) 75 (63–88)§§ 101 (95–104) <0.001
FEV1/FVC 0.78 (0.73–0.83)# 0.82 (0.78–0.88) 0.85 (0.81–0.86) 0.03
TLCO, percentage of predicted 92 (77–102)## 57 (53–69)§§ 103 (98–109) 0.01
Data are shown as median (IQR) unless otherwise stated. ∗𝑃 values represent pairwise comparison between Sarcoidosis and healthy controls with Mann-
Whitney 𝑈 test conducted if significant differences were found with Kruskal-Wallis test. §§𝑃 < 0.01 compared to healthy controls. #𝑃 < 0.05 and ##𝑃 < 0.01
compared to other DPLD. ∗∗𝑃 value from chi-squared test. DPLD: diffuse parenchymal lung disease; FEV1: forced expiratory volume in 1 second; FVC: forced
vital capacity; TLCO: transfer factor of the lung for carbon monoxide.
2.5. Antibody Staining and Flow Cytometry. For surface
antigen staining, BALF was centrifuged for 5min at 500×g,
and the cell pellet incubated for 15min with the antibodies
as listed (supplementary Table 1, tubes 1-2). For detection of
FoxP3+ CD4+ T cells, the unstimulated cells were incubated
with permeabilization buffer (BD Biosciences) and then
stained with antibodies to surface and intracellular antigens
(supplementary Table 1, tube 3). In the mitogen-stimulated
samples, the thawed cells were incubated with permeabiliza-
tion buffer (BDBiosciences) and then stainedwith antibodies
to surface and intracellular antigens (supplementary Table 1,
tube 4). Unstimulated cells were used as negative controls for
gating.
A minimum of 10 000 and 50 000 cells were analysed for
surface and intracellular antigens, respectively, using a FACS
Canto I flow cytometer (BD Biosciences), with FACS DIVA
software (BD Biosciences). Lymphocytes were identified by
their low side scatter (SSc) and forward scatter (FSc), and
T cells were identified as CD3+ lymphocytes. T cells were
further gated by expression of CD4 and CD8 into the two
main subsets, CD4+ and CD8+ (cytotoxic) T cells. Gating of
CD4+ T cell subsets is displayed in Figure 1.
2.6. Statistical Methods. Group comparison for continuous
and categorical data was done by Kruskal-Wallis test and
Pearson chi-squared test, respectively. Pairwise comparison
was donewithMann-WhitneyU test if a significant difference
was found with Kruskal-Wallis test. Spearman’s rank corre-
lation test was used for investigating correlation. Statistical
analyses were done in R, a language and environment
for statistical computing (R Core Team, R Foundation for
Statistical Computing, Vienna, Austria). A 𝑃 value of < 0.05
was considered to be statistically significant.
3. Results
3.1. FoxP3+ CD4+ T Cells. The fraction of FoxP3+ CD4+
T cells in BALF was significantly lower in patients with
sarcoidosis compared to other DPLDs and HCs (median
(IQR): 3.4% (2.1–4.8) versus 7.1% (4.4–12.6), 𝑃 = 0.001 and
versus 5.3% (4.4–7.0), 𝑃 = 0.017) (Figure 2(a)).
Themajority of FoxP3+ CD4+ T cells expressedCD27 and
CD39 in all groups, with no significant differences between
sarcoidosis and healthy controls (𝑃 = 0.063 and 𝑃 = 0.51,
resp.) (Table 2). Expression of CD27 and CD39 on FoxP3+
CD4+ T cells was higher in other DPLDs compared to
sarcoidosis (𝑃 = 0.01 and 𝑃 = 0.03, resp.), and in other
DPLDs compared to healthy controls (𝑃 = 0.001 and 𝑃 =
0.02, resp.).
3.2. Th17, IFN-𝛾+ Th17, and Th1 Cells. Compared to healthy
control subjects, the Th17 cell fraction of CD4+ T cells was
45% lower (𝑃 = 0.011) and the proportion of Th17 cells
positive for IFN-𝛾 was over twofold greater (𝑃 = 0.0005) in
sarcoidosis (Figure 2 and Table 3). These fractions were not
significantly different between patients with sarcoidosis and
other DPLDs. Fractions ofTh1 (IFN-𝛾+ CD4+) cells were not
significantly different between any of the groups.
Flow cytometry dot plots with a display of FoxP3+ CD4+
T cells,Th1,Th17, and IFN-𝛾+Th17 cells from a representative
sarcoidosis and control subject are shown in Figure 1.
The fraction of IFN-𝛾+ Th17 cells increased with radio-
logic stage of sarcoidosis (𝑛 = 23, rho = 0.45, and 𝑃 = 0.03)
(Figure 3).
3.3. The Relationship between Th1, Th17, IFN-𝛾+ Th17, and
FoxP3+ CD4+ T Cell Subsets in Sarcoidosis. In patients with
sarcoidosis, fractions ofTh17 cells weremoderately correlated
to fractions of Th1 cells (𝑁 = 23, rho = 0.53, and 𝑃 = 0.009),
while we found no significant correlation between Th17 cells
and FoxP3+ T helper cells (𝑁 = 23, rho = 0.25, and 𝑃 = 0.26)
or between Th1 cells and FoxP3+ T helper cells (𝑁 = 23,
rho = −0.25, and 𝑃 = 0.26).
IFN-𝛾+ fractions ofTh17 cells were highly correlated with
Th1 cells in patients with sarcoidosis (𝑁 = 23, rho = 0.64, and
𝑃 = 0.001). This correlation was also found in an analysis of
all patients and healthy controls combined (𝑁 = 48, rho =
0.75, 𝑃 < 0.0001) (Figure 4(a)), and in the other individual
groups (healthy controls:𝑁 = 15, rho = 0.91, and𝑃 < 0.00001
and other DPLDs: 𝑁 = 11, rho = 0.7, and 𝑃 = 0.02).
The ratio of Th17/FoxP3+ CD4+ T cells was not significantly
different between the groups (𝑃 = 0.09, Kruskal-Wallis test),
while the ratio of Th1/FoxP3+ CD4+ T cells was higher in
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Figure 1: T helper cells in bronchoalveolar lavage fluid: regulatory T cells, Th1, Th17, and IFN-𝛾+ Th17 cells. Flow cytometry dot plots of
bronchoalveolar lavage fluid CD4+ T cells gated by expression of FoxP3, IL17 (synonymous to IL-17A), and IFN-𝛾 from a healthy control
subject ((a)–(c)) and a patient with sarcoidosis ((d)–(f)). The T cell subsets are defined as follows: Th1 cells: IFN-𝛾+ CD4+; Th17 cells: IL17+
CD4+; regulatory T cells: FoxP3+ CD4+ and IFN-𝛾+; Th17 cells: IFN-𝛾+ IL-17+ CD4+. Thus, the Th17 cells include the cells in both upper
quadrants of plots (c) and (f). The patient and healthy control are representative examples. Gates for IL17 and IFN-𝛾 were set according to
unstimulated CD4+ T cells. Very few cells express intracellular IL-17 or IFN-𝛾 prior to stimulation (median 0.0% in fractions of CD4+ T cells
for both IL-17 and IFN-𝛾).
Table 2: BALF lymphocyte subsets assessed by flow cytometry.
Characteristic Sarcoidosis(𝑁 = 30)
Other DPLDs
(𝑁 = 18)
Healthy controls
(𝑁 = 15) 𝑃
∗
CD3+ T cells (% of lymphocytes) 96.2 (95.3–97.5)## 92.3 (87.0–94.6) 92.9 (89.7–94.6) <0.0001
CD4/CD8 ratio 6.1 (4.1–10.8)## 2.0 (0.5–3.3) 2.6 (2.1–3.4) <0.0001
HLA-DR+ (% of CD4+ T cells) 75.1 (60.9–80.7) 76.1 (70.2–84.4)§§ 44.9 (36.1–56.7) <0.0001
HLA-DR+ (% of CD8+ T cells) 47.3 (42.2–56.3)## 70.0 (58.6–78.1)§§ 30.4 (25.9–33.9) <0.0001
FoxP3+ (% of CD4+ T cells) 3.4 (2.1–4.8)## 7.1 (4.4–12.6) 5.3 (4.4–7.0) 0.02
CD39+ (% of FoxP3+ CD4+ T cells) 61 (34–78)# 80 (68–84)§ 55 (45–66) 0.51
CD27+ (% of FoxP3+ CD4+ T cells) 86 (80–93)# 95 (87–97)§§ 78 (72–86) 0.06
Data are shown as median (IQR). ∗𝑃 values represent pairwise comparison between sarcoidosis and healthy controls with Mann-Whitney𝑈 test conducted if
significant differences were found with Kruskal-Wallis test. §𝑃 < 0.05 and §§𝑃 < 0.01 compared to healthy controls. #𝑃 < 0.05 and ##𝑃 < 0.01 compared to
other DPLD.
sarcoidosis compared to other DPLDs and compared to HC
(median (IQR): 21.7 (14.4–35.2) versus 6.2 (2.8–13.5), 𝑃 =
0.002, and versus 9.5 (8.9–13-6), 𝑃 = 0.009).The ratio of IFN-
𝛾
+Th17/FoxP3+ CD4+ T cells was considerably increased in
sarcoidosis compared to other DPLDs or HC (Figure 4(b)).
The lymphocyte fraction was 2.5-fold greater in patients
with sarcoidosis compared to HC (Table 4). BALF lympho-
cyte subset fractions in the study groups are summarized in
Table 2. The CD4/CD8 ratio, HLA-DR+ CD4+, and HLA-
DR+ CD8+ T cells were significantly higher in patients with
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Figure 2: Bronchoalveolar lavage fluid fractions of FoxP3+ CD4+ T cells, Th17, and IFN-𝛾+Th17 in sarcoidosis, other DPLDs, and healthy
control subjects. (a) Lower fractions of regulatory T cells, defined as FoxP3+ CD4+ T cells, in sarcoidosis compared to other DPLDs and
HC. (b) Lower Th17 cell fractions of CD4+ T cells in sarcoidosis compared to HC (median: 2.5% versus 4.5%, 𝑃 = 0.011). (c) Higher IFN-
𝛾
+ fraction of Th17 cells in sarcoidosis compared to HC (median: 72.4% versus 31%, 𝑃 = 0.0005). Pairwise comparisons were done with
Mann-Whitney U test. DPLD: Diffuse parenchymal lung disease; HC: healthy controls.
sarcoidosis compared to HC (𝑃 < 0.0001, 𝑃 < 0.0001, and
𝑃 < 0.0001, resp.). Expression of HLA-DR on CD8+ T cells
was higher in other DPLDs compared to healthy controls and
sarcoidosis (𝑃 = 0.0001 and 𝑃 = 0.0008, resp.) and on CD4+
T cells compared to healthy controls (𝑃 = 0.0002).
4. Discussion
In this study, IFN-𝛾 expression in Th17 cells was over
twofold greater in sarcoidosis than in healthy controls and
increased with the radiologic stage of sarcoidosis. Fractions
of BALF FoxP3+ CD4+ T cells and Th17 cells were lower in
sarcoidosis compared to healthy controls. Furthermore, we
found a high degree of correlation between fractions of IFN-
𝛾
+ Th17 and Th1 cells, and the ratio of IFN-𝛾+ Th17/FoxP3+
CD4+ T cells was prominently increased in sarcoidosis
compared to other DPLDs or HCs. This may indicate a
strongTh1 immune response in sarcoidosis patients resulting
in deviation of CD4+ T cell differentiation from FoxP3+
CD4+ T cells and plain Th17 cells into IFN-𝛾+Th17 and Th1
cells.
To our knowledge, investigation of BALF IFN-𝛾+ Th17
cells in sarcoidosis is limited to one study by ten Berge et al.
[32]. In that study expression of IFN-𝛾was reported in a large
fraction of BALFTh17 cells in 5 patients. Our finding, stating
that themajority of BALFTh17 cells in sarcoidosis are IFN-𝛾+,
is in line with reports on Th17 cells in peripheral blood from
patients with sarcoidosis [19, 32]. In the study by Richmond
et al., peripheral blood IFN-𝛾+ Th17 cells of sarcoidosis
patients had significantly lower mean fluorescence intensity
for IFN-𝛾 compared to cells from control subjects, indicating
a reduced capacity in these cells to produce IFN-𝛾 [19]. In
sarcoidosis, T cells exhibit a more differentiated phenotype
in the affected organ [33, 34]. Thus, the immune process in
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Table 3: BALF lymphocyte subsets assessed by flow cytometry of mitogen stimulated cells.
Mitogen stimulated cells Sarcoidosis(𝑁 = 23)
Other DPLDs
(𝑁 = 11)
Healthy controls
(𝑁 = 15) 𝑃
∗
Th1 (IFN-𝛾+, % of CD4+ T cells) 75.5 (62.6–79.4) 62.1 (46.7–75.0) 65.7 (41.5–69.6) n.s
Th17 cells (% of CD4+ T cells) 2.5 (1.4–4.5) 3.0 (1.8–6.6) 4.5 (3.2–8.5) 0.01
IFN-𝛾+Th17 (% of Th17) 72.4 (57.1–83.8) 65.5 (39.9–85.9) 31.0 (22.3–49.6) 0.0005
IFN-𝛾+ CD8+ T cells (% of CD8+) 83.4 (69.3–87.9) 83.1 (76.4–94.3) 85.5 (77.5–89.9) n.s
IL17+ CD8+ T cells (% of CD8+) 0.8 (0.5–2.4) 0.5 (0.3–1.4) 1.1 (0.9–1.6) n.s
Data are shown as median (IQR). ∗𝑃 values represent pairwise comparison between sarcoidosis and healthy controls with Mann-Whitney𝑈 test conducted if
significant differences were found with Kruskal-Wallis test. Pairwise comparisons between sarcoidosis and other DPLD or other DPLD and healthy controls
showed no significant difference. n.s: nonsignificant (Kruskal-Wallis test).
Table 4: BALF cellular differential counts assessed by microscopy.
Sarcoidosis
(𝑁 = 30)
Other DPLDs
(𝑁 = 17)
Healthy controls
(𝑁 = 14) 𝑃
∗
Total cell concentration (106/mL) 19 (15–28) 26 (11–29) 14 (12–17) 0.01
Lymphocytes (%) 35 (24–53) 34 (14–48)§ 14 (10–25) 0.001
Neutrophils (%) 2 (1–4)## 6 (2–9) 3 (2–5) 0.15
Mast cells (per 10 squares) 4 (2–9)## 21 (8–63)§§ 2 (0–5) 0.04
Eosinophils (%) 0 (0-1)## 3 (1–9)§§ 0 (0-0) 0.14
Alveolar macrophages (%) 60 (45–73) 47 (26–74)§§ 81 (69–85) 0.001
Data are shown as median (IQR). ∗𝑃 values represent pairwise comparison between sarcoidosis and healthy controls with Mann-Whitney𝑈 test conducted if
significant differences were found with Kruskal-Wallis test. §𝑃 < 0.05 and §§𝑃 < 0.01 compared to healthy controls. #𝑃 < 0.05 and ##𝑃 < 0.01 compared to
other DPLD. Differential counts were missing for one patient with other diffuse parenchymal lung disease (DPLD) and one healthy control.
sarcoidosis may be better characterized in studies on BALF
cells.
Fractions of BALF Th17 cells were lower in sarcoidosis
patients compared to controls in the present study. This
is consistent with another study in which IL-17A mRNA
expression in sorted CD4+ T cells was investigated [35],
but at variance with other studies that detected intracellular
expression of IL-17A by flow cytometry [14, 19, 32], several
possible explanations may account for the different results.
The gating of IL17+ from IL17− CD4+ T cells may differ
between the studies. We used unstimulated cells from the
individual patients to set the gates, which we thinkmay be an
appropriate way to delineate the IL17+ from the IL17− popu-
lations. Importantly, differences in genetic background may
influence the sarcoidosis immune process. Our results are
similar to those of the study from Sweden [35], but at variance
with theAmerican study [19], where approximately half of the
patients had Afro-American background, and 14/37 patients
had sarcoidosis of the skin. In contrast, all of our patients
had pulmonary sarcoidosis. In addition, Lo¨fgren’s syndrome
is more frequent in sarcoidosis in Scandinavia.
In the present study, the FoxP3+ fractions of CD4+ T cells
in sarcoidosis were lower than in HC. This is in agreement
with one previous study, which reported decreased frequency
of FoxP3+ CD4+ T cells in BALF in patients compared to
HC [22], with relative fractions resembling our results. In
that study FoxP3 mRNA expression was also investigated
and found to be lower in BALF CD4+ T cells from patients
compared toHC. In another study, regulatory T cells in BALF
and peripheral blood were found to be higher in patients
with sarcoidosis than in control subjects [20]. However, they
defined regulatory T cells as CD25bright CD4+ T cells and
confirmed the expression of FoxP3 by, on average, 86.5% of
these cells by a single cell PCR approach. Later, the same
group reported increased fractions of CD45RA−FoxP3bright
CD4+ T cells in peripheral blood and CD4+ FoxP3+ cells
in lymph nodes and granulomas of patients with active
sarcoidosis [36]. The definition of regulatory T cells as
FoxP3bright CD4+ T cells is also different than in the present
study, where regulatory T cells are defined as FoxP3+ CD4+ T
cells,making direct comparison less relevant. As documented
by Darlington et al., FoxP3+ CD4+ T cells are augmented in
lymph nodes compared to BALF [37], thus our finding of
lower fractions of regulatory T cells in BALF in sarcoidosis
may not be inconsistent with increased fractions in lymph
nodes and granulomas.
IFN-𝛾+ Th17 cells may represent a pathogenic subset of
Th17 cells in some autoimmune diseases [17, 18]. In one
study, human Candida albicans-specific but not Staphylococ-
cus aureus-specific Th17 cells were demonstrated to produce
IFN-𝛾 upon stimulation [15]. During the last few years it
has become increasingly clear that there exists plasticity in
the differentiation of T helper cells [38]. IL-12 and IFN-𝛾
influence Th17 cells to change towards IFN-𝛾+ Th17 cells or
Th1-like cells [16, 39]. In a study on Th17 cells recovered
from diseased gut areas in colitis patients, a median of ∼
40% of the Th17 cells was also IFN-𝛾+ [40]. In sarcoidosis,
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Figure 3: Fractions of IFN-𝛾+Th17 cells increase with radiological
stage in sarcoidosis. The relationship of IFN-𝛾+ Th17 cells and
radiological stage in patients with sarcoidosis (𝑁 = 23) and healthy
control subjects (𝑁 = 15). Fractions of IFN-𝛾+ Th17 cells increase
with advancing stage (𝑁 = 23, Spearman’s rho = 0.454, and 𝑃 =
0.03). Bars represent median. HC: Healthy control subjects.
macrophages andTh1-cells are enriched in the granulomatous
lung tissue, and the dominating cytokines in the feedback
loop between these cells are IL-12 and IFN-𝛾. Accordingly,
the reduced Th17 and increased IFN-𝛾+ Th17 cells that we
detected in BALF from the sarcoidosis patients might be a
result of dominating Th1-driving transcription factors and
cytokines. In Figure 4(a) we show that in BALF from patients
and HC there seems to be a clear-cut and highly significant
linear correlation between Th1 cells as a fraction of CD4+ T
cells and IFN-𝛾+ Th17 cells as a fraction of Th17 cells. This
might favor an idea of a common mechanism in switching
of Th17 towards IFN-𝛾+ Th17 and expansion of Th1 cells.
Conversely, it has recently been demonstrated in experiments
with mice, in whom the Th1-driving transcription factors
had been knocked out in T cells, that such na¨ıve T cells
can still develop into pathogenic IFN-𝛾+ Th17 cells and
that IL-23 is essential for differentiation and expansion of
these cells [18]. It may thus seem to be, at least in mice,
a way of differentiation for IFN-𝛾+ Th17 cells independent
of the IFN-𝛾 driving transcription factors. The observation
that the relative frequency of IFN-𝛾+ Th17 cells is higher in
patients with advanced sarcoidosis stage (Figure 3) might be
an indication that these cells possibly have a deleterious effect
in sarcoidosis or might just be the consequence of a more
dominating and pathogenic Th1 immune reaction.
The ratio between IFN-𝛾+ Th17 cells and FoxP3+ CD4+
T cells is markedly raised in patients with sarcoidosis in our
study. Many studies have shown a reciprocal relationship
between Th17 and regulatory T cells [26], and autoimmune
diseases often result from an imbalance in these CD4+ T cell
subsets [41]. An increased ratio between IFN-𝛾+ Th17 cells
and FoxP3+ CD4+ T cells may represent a corresponding
feature of sarcoidosis. A recent study reported an increased
Th17/regulatory T cell ratio in peripheral blood and BALF
in sarcoidosis compared to healthy controls [42]. This was
not found in our study, and fractions of Th17 cell in BALF
were decreased in our study and increased in their study. Both
genetic background and environmental exposures may differ
between a Scandinavian and aChinese population of patients,
possibly accounting for some of these observed differences.
In the present study, CD4+ T cells fromBALF are studied,
which aremore directly involved in the immunologic process
of sarcoidosis than peripheral blood cells. However, there are
some limitations to the study. In our clinic, the number of
patients with other DPLD diagnoses is small, and patients
consist of many different entities. A comparison with a
sufficient number of patients with other granulomatous lung
diseases would be of interest. Furthermore, the number of
sarcoidosis patients in different radiological stages is small,
limiting the use of our data in investigating differences
between patients in different stages of the disease.
In conclusion, we found that the majority of BALF Th17
cells in sarcoidosis are IFN-𝛾+, and the fraction of IFN-𝛾+
Th17 cells was highly correlated with the fraction ofTh1 cells.
Fractions of both Th17 cells and FoxP3+ CD4+ T cells were
lower in sarcoidosis than in HC, and we found a highly
elevated ratio between IFN-𝛾+ fractions of Th17 cells and
FoxP3+ CD4+ T cells, possibly indicating an immune cell
imbalance. Despite the explanation offered in this paper
that the generation of IFN-𝛾+ Th17 cells may be a direct
consequence of aTh1-polarized cytokinemilieu onTh17 cells,
they may still represent a pathogenic subset of Th17 cells,
and further characterization of these cells may provide a
target for therapy and provide additional clues to the complex
immunopathology of sarcoidosis. Functional studies on these
cells and investigations of these cells in patients with different
disease course are warranted.
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